Teva’s Copaxone prevents MS relapses

Phase III clinical trials using 40mg Copaxone three times a week on 1400 Multiple Sclerosis patients in 155 sites worldwide, resulted in a 34.4% reduction in relapse rates.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *